Polycystic Ovary SyndromeNCT06968455
Endocrine Disruptors, Toxic and Essential Chemical Elements and Polycystic Ovary Syndrome
An observational study of Polycystic Ovary Syndrome, run by University Medical Centre Ljubljana at 1 site in Slovenia.
Trial summary
Studies have shown that endocrine disruptors (EDs) and toxic and essential chemical elements affect women's reproductive health and may play a role in the development of polycystic ovary syndrome (PCOS). Read more about this study
- Who is it for?
- Ages 20 to 39 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Polycystic Ovary Syndrome
- What is being tested?
- parabens
- How many people
- 70 participants
- Where
- 1 siteSlovenia
- Study dates
- 3 Jan 2023to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 39 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Women attending the Division of Ob/Gyn, University Medical Centre Ljubljana, for PCOS treatment or a regular periodic gynecological check-up.
Who may be able to join
- body mass index (BMI) between 18.5 and 29.9 kg/m2
- fulfilling two of the three Rotterdam diagnostic criteria for the diagnosis of PCOS: oligo- or anovulation, ultrasound-visible morphological picture of PCO (presence of 12 or more follicles of size 2-9 mm in one of the ovaries) and/or clinical/biochemical signs of hyperandrogenism (study group)
- a regular menstrual cycle of 21 to 35 days (control group)
Who cannot join
- pregnancy
- hormonal treatment in the last 3 months (hormonal contraception, hormone replacement therapy, progestogens)
- hyperprolactinemia
- hypothyroidism, hyperthyroidism
- known premature ovarian failure, primary amenorrhea
- chronic diseases: diabetes, depression, Crohn's disease, celiac disease, cardiovascular diseases, liver and kidney disease, asthma, chronic obstructive pulmonary disease, diseases of the musculoskeletal system, neurological diseases, oncological diseases.
Trial locations and contacts
1 site in 1 country.
Slovenia1 site
Division of Ob/Gyn, University Medical Centre Ljubljana
Ljubljana, 1000
About this study
Official title: The Association of Endocrine Disruptors and Toxic and Essential Chemical Elements With Polycystic Ovary Syndrome
Studies have shown that endocrine disruptors (EDs) and toxic and essential chemical elements affect women's reproductive health and may play a role in the development of polycystic ovary syndrome (PCOS). There is little research examining the association of EDs and toxic and essential chemical elements with PCOS, and for some chemical compounds there is none. In our study, we will examine the relationship of EDs (bisphenols, parabens, triclosan) and toxic (cadmium-Cd, lead-Pb, mercury-Hg, arsenic-As) and essential chemical elements (selenium-Se, copper-Cu, zinc-Zn, manganum-Mn, molibdenum-Mo) in biological samples (blood, urine) of women with PCOS. Main hypothesis is that the levels of EDs, toxic chemical elements and molibdenum-Mo in the biological samples of PCOS women will be higher, and the levels of essential chemical elements will be lower than in the control group and related to the altered liver and kidney function and to the women's lifestyle and the environment they live in.
Read the detailed description
Endocrine disruptors are externally introduced chemical substances or mixtures of substances that, through altering hormone functions, cause unwanted effects on the health of an individual or its offspring or (sub)population. They are ubiquitous in the environment in polycarbonate plastic and plastic packaging (bisphenols) or in cosmetic and pharmaceutical products (parabens, triclosan). They enter the body through food and drinking water consumption, through inhaled air and contact with the skin. Studies have shown that EDs, especially bisphenols (e.g., bisphenol A-BPA, bisphenol S-BPS, bisphenol F-BPF), parabens and triclosan, through their impact on steroid receptors and epigenetic modifications, have a negative effect on women's reproductive health. Exposure to toxic and essential chemical elements can trigger the formation of reactive oxygen species, which affects steroidogenesis and metabolic processes.
The heterogeneity of the clinical picture in PCOS suggests that, in addition to genetic factors, environmental factors and lifestyle might also be involved in the etiopatoghenesis of the syndrome. Therefore, EDs are also the subject of research for a possible role in the development of PCOS. Some studies have confirmed elevated levels of BPA in the blood and urine of women with PCOS. The positive correlation of BPS with PCOS has been confirmed in only one study so far. The only study assessing blood levels of parabens in women with PCOS found no association with PCOS. So far, only two studies have examined the association of triclosan with PCOS, with conflicting results. Elevated levels of toxic chemical elements (e.g., Cd, Pb, Hg, As) and reduced levels of essential elements (e.g., Se, Zn) can also play a role in the development of PCOS. There are no studies assessing the role of Mo in PCOS. Since the current data on association of EDs and toxic and essential chemical elements with PCOS is scarce, the information obtained in our research could allow us to give an expert opinion on additional diagnostic tests and future recommendations on how to avoid the negative impact of EDs, toxic and essential chemical elements.
The research will be conducted at the Division of Obstetrics and Gynaecology, University Medical Centre Ljubljana, with the collaboration of the Clinical Research Centre, University Medical Centre Ljubljana, Institute of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, and Jožef Stefan Institute. The study will be a prospective case-control study. The required number of samples was estimated based on one of the few published studies, where the presence of BPA was found in 95 % of PCOS women, while in the control group this proportion was 70 %. When analyzing the study power, we considered the standard values for alpha = 0.05 and a power of 80%. With these assumptions, we would need 35 women in each group. Women will be introduced to the study when treated for PCOS (study group) or attending the Division of Obstetrics and Gynaecology, University Medical Centre Ljubljana, for a regular periodic gynecological check-up (control group). After signing the informed consent form, clinical examination and transvaginal ultrasound with the antral follicle count will be performed. Each woman will fill in the questionnaire regarding her health status, fertility, pregnancies, deliveries, region of permanent residence, home and workplace environment, dietary and lifestyle habits, smoking and education. On the day 2 to 5 of regular menstrual cycle or after two or more months after last menstrual period in the case of oligo- or amenorrhea, fasting venous blood sample and first morning urine will be taken at the Institute of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, for analysis of the content of bisphenols (BPA, BPS and BPF), parabens, triclosan, chemical elements (toxic - Cd, Pb, Hg and As, and essential - Se, Cu, Zn, Mn, Mo), blood count, liver and kidney function tests, Antimüllerian hormone-AMH, sex hormone binding globuline- SHBG and reproductive hormones (FSH, LH, PRL, TSH, estradiol, progesterone, testosterone, androstenedione, dehydroepiandrosterone sulfate). The analysis of EDs and chemical elements will be carried out at the Jožef Stefan Institute, while other diagnostic tests will be carried out at the Clinical Institute for Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, where the collection of biological samples will also take place. The protection of personal data will be guaranteed, as each blood sample will be labelled or recorded during the study under a code identical to the code of the questionnaire completed by the patient. The statistical evaluation of the data will be carried out at the University Medical Centre Ljubljana, Jožef Stefan Institute, and the Faculty of Medicine, University of Ljubljana. Appropriate statistical models, e.g., multiple linear regression, will be used to determine the relationship between EDs exposure, PCOS and lifestyle.
- Conditions
- Polycystic Ovary Syndrome
- Being tested
- parabens
- Keywords
- PCOS, endocrine disrupting chemicals, bisphenol A, parabens, triclosan, heavy metals
- Medical subject headings
- Polycystic Ovary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
parabensOther
endocrine disruptors
| Study group | Role | What they receive |
|---|---|---|
| PCOS study group | PCOS patients aged 20 to 39 years Receives: Other: parabens | |
| healthy control group | Healthy women aged 20 to 39 years Receives: Other: parabens |
What is being measured
The primary outcome is the main question the study is designed to answer.
Levels of EDs, toxic and essential chemical elements in biological samples (blood, urine)
blood and urine levels
Measured: 1 month
Secondary outcomes (2)
liver and kidney function
biochemical testa
Measured: 1 month
reproductive hormone blood levels
blood levels
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2025
- Study start3 Jan 2023
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Polycystic Ovary SyndromeStudies of the same condition, open and under way.
- More trials run by University Medical Centre LjubljanaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Medical Centre Ljubljana
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Irma Virant-Klun, PhD, Principal investigator, Clinical Research Centre, University Medical Centre Ljubljana
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06968455
- Sponsor's protocol ID
- TP20220007
- Status last verified
- May 2025
- First submitted
- 5 May 2025
- Last updated
- 13 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: It is not yet known if there will be a plan to make IPD available.
Publications
Rattan S, Zhou C, Chiang C, Mahalingam S, Brehm E, Flaws JA. Exposure to endocrine disruptors during adulthood: consequences for female fertility. J Endocrinol. 2017 Jun;233(3):R109-R129. doi: 10.1530/JOE-17-0023. Epub 2017 Mar 29.
PubMed 28356401Yilmaz B, Terekeci H, Sandal S, Kelestimur F. Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention. Rev Endocr Metab Disord. 2020 Mar;21(1):127-147. doi: 10.1007/s11154-019-09521-z.
PubMed 31792807Chiang C, Mahalingam S, Flaws JA. Environmental Contaminants Affecting Fertility and Somatic Health. Semin Reprod Med. 2017 May;35(3):241-249. doi: 10.1055/s-0037-1603569. Epub 2017 Jun 28.
PubMed 28658707Ye J, Zhu W, Liu H, Mao Y, Jin F, Zhang J. Environmental exposure to triclosan and polycystic ovary syndrome: a cross-sectional study in China. BMJ Open. 2018 Oct 17;8(10):e019707. doi: 10.1136/bmjopen-2017-019707.
PubMed 30337305
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Association of Endocrine Disruptors and Toxic and Essential Chemical Elements With Polycystic Ovary Syndrome
- ClinicalTrials.gov ID
- NCT06968455
- Acronym / sponsor ID
- TP20220007
- Conditions
- Polycystic Ovary Syndrome
- Keywords
- PCOS, endocrine disrupting chemicals, bisphenol A, parabens, triclosan, heavy metals
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- University Medical Centre LjubljanaUniversity, hospital or other
- Study start
- 3 Jan 2023 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 13 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Studies have shown that endocrine disruptors (EDs) and toxic and essential chemical elements affect women's reproductive health and may play a role in the development of polycystic ovary syndrome (PCOS). There is little research examining the association of EDs and toxic and essential chemical elements with PCOS, and for some chemical compounds there is none. In our study, we will examine the relationship of EDs (bisphenols, parabens, triclosan) and toxic (cadmium-Cd, lead-Pb, mercury-Hg, arsenic-As) and essential chemical elements (selenium-Se, copper-Cu, zinc-Zn, manganum-Mn, molibdenum-Mo) in biological samples (blood, urine) of women with PCOS. Main hypothesis is that the levels of EDs, toxic chemical elements and molibdenum-Mo in the biological samples of PCOS women will be higher, and the levels of essential chemical elements will be lower than in the control group and related to the altered liver and kidney function and to the women's lifestyle and the environment they live in.
Detailed description
Endocrine disruptors are externally introduced chemical substances or mixtures of substances that, through altering hormone functions, cause unwanted effects on the health of an individual or its offspring or (sub)population. They are ubiquitous in the environment in polycarbonate plastic and plastic packaging (bisphenols) or in cosmetic and pharmaceutical products (parabens, triclosan). They enter the body through food and drinking water consumption, through inhaled air and contact with the skin. Studies have shown that EDs, especially bisphenols (e.g., bisphenol A-BPA, bisphenol S-BPS, bisphenol F-BPF), parabens and triclosan, through their impact on steroid receptors and epigenetic modifications, have a negative effect on women's reproductive health. Exposure to toxic and essential chemical elements can trigger the formation of reactive oxygen species, which affects steroidogenesis and metabolic processes.
The heterogeneity of the clinical picture in PCOS suggests that, in addition to genetic factors, environmental factors and lifestyle might also be involved in the etiopatoghenesis of the syndrome. Therefore, EDs are also the subject of research for a possible role in the development of PCOS. Some studies have confirmed elevated levels of BPA in the blood and urine of women with PCOS. The positive correlation of BPS with PCOS has been confirmed in only one study so far. The only study assessing blood levels of parabens in women with PCOS found no association with PCOS. So far, only two studies have examined the association of triclosan with PCOS, with conflicting results. Elevated levels of toxic chemical elements (e.g., Cd, Pb, Hg, As) and reduced levels of essential elements (e.g., Se, Zn) can also play a role in the development of PCOS. There are no studies assessing the role of Mo in PCOS. Since the current data on association of EDs and toxic and essential chemical elements with PCOS is scarce, the information obtained in our research could allow us to give an expert opinion on additional diagnostic tests and future recommendations on how to avoid the negative impact of EDs, toxic and essential chemical elements.
The research will be conducted at the Division of Obstetrics and Gynaecology, University Medical Centre Ljubljana, with the collaboration of the Clinical Research Centre, University Medical Centre Ljubljana, Institute of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, and Jožef Stefan Institute. The study will be a prospective case-control study. The required number of samples was estimated based on one of the few published studies, where the presence of BPA was found in 95 % of PCOS women, while in the control group this proportion was 70 %. When analyzing the study power, we considered the standard values for alpha = 0.05 and a power of 80%. With these assumptions, we would need 35 women in each group. Women will be introduced to the study when treated for PCOS (study group) or attending the Division of Obstetrics and Gynaecology, University Medical Centre Ljubljana, for a regular periodic gynecological check-up (control group). After signing the informed consent form, clinical examination and transvaginal ultrasound with the antral follicle count will be performed. Each woman will fill in the questionnaire regarding her health status, fertility, pregnancies, deliveries, region of permanent residence, home and workplace environment, dietary and lifestyle habits, smoking and education. On the day 2 to 5 of regular menstrual cycle or after two or more months after last menstrual period in the case of oligo- or amenorrhea, fasting venous blood sample and first morning urine will be taken at the Institute of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, for analysis of the content of bisphenols (BPA, BPS and BPF), parabens, triclosan, chemical elements (toxic - Cd, Pb, Hg and As, and essential - Se, Cu, Zn, Mn, Mo), blood count, liver and kidney function tests, Antimüllerian hormone-AMH, sex hormone binding globuline- SHBG and reproductive hormones (FSH, LH, PRL, TSH, estradiol, progesterone, testosterone, androstenedione, dehydroepiandrosterone sulfate). The analysis of EDs and chemical elements will be carried out at the Jožef Stefan Institute, while other diagnostic tests will be carried out at the Clinical Institute for Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, where the collection of biological samples will also take place. The protection of personal data will be guaranteed, as each blood sample will be labelled or recorded during the study under a code identical to the code of the questionnaire completed by the patient. The statistical evaluation of the data will be carried out at the University Medical Centre Ljubljana, Jožef Stefan Institute, and the Faculty of Medicine, University of Ljubljana. Appropriate statistical models, e.g., multiple linear regression, will be used to determine the relationship between EDs exposure, PCOS and lifestyle.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PCOS study group | – | Other: parabensPCOS patients aged 20 to 39 years |
| healthy control group | – | Other: parabensHealthy women aged 20 to 39 years |
Who may qualify
- Ages
- 20 to 39 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Women attending the Division of Ob/Gyn, University Medical Centre Ljubljana, for PCOS treatment or a regular periodic gynecological check-up.
Key inclusion criteria (3 listed)
- body mass index (BMI) between 18.5 and 29.9 kg/m2
- fulfilling two of the three Rotterdam diagnostic criteria for the diagnosis of PCOS: oligo- or anovulation, ultrasound-visible morphological picture of PCO (presence of 12 or more follicles of size 2-9 mm in one of the ovaries) and/or clinical/biochemical signs of hyperandrogenism (study group)
- a regular menstrual cycle of 21 to 35 days (control group)
Key exclusion criteria (6 listed)
- pregnancy
- hormonal treatment in the last 3 months (hormonal contraception, hormone replacement therapy, progestogens)
- hyperprolactinemia
- hypothyroidism, hyperthyroidism
- known premature ovarian failure, primary amenorrhea
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| parabensendocrine disruptors | Other | PCOS study group, healthy control group |
Primary outcome
Levels of EDs, toxic and essential chemical elements in biological samples (blood, urine)
Time frame: 1 month
blood and urine levels
2 secondary outcomes
liver and kidney function
Time frame: 1 month
reproductive hormone blood levels
Time frame: 1 month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2025.
- Background: PubMed 28356401Rattan S, Zhou C, Chiang C, Mahalingam S, Brehm E, Flaws JA. Exposure to endocrine disruptors during adulthood: consequences for female fertility. J Endocrinol. 2017 Jun;233(3):R109-R129. doi: 10.1530/JOE-17-0023. Epub 2017 Mar 29.
- Background: PubMed 31792807Yilmaz B, Terekeci H, Sandal S, Kelestimur F. Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention. Rev Endocr Metab Disord. 2020 Mar;21(1):127-147. doi: 10.1007/s11154-019-09521-z.
- Background: PubMed 28658707Chiang C, Mahalingam S, Flaws JA. Environmental Contaminants Affecting Fertility and Somatic Health. Semin Reprod Med. 2017 May;35(3):241-249. doi: 10.1055/s-0037-1603569. Epub 2017 Jun 28.
- Background: PubMed 30337305Ye J, Zhu W, Liu H, Mao Y, Jin F, Zhang J. Environmental exposure to triclosan and polycystic ovary syndrome: a cross-sectional study in China. BMJ Open. 2018 Oct 17;8(10):e019707. doi: 10.1136/bmjopen-2017-019707.
- PubMedLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. It is not yet known if there will be a plan to make IPD available.
Related trials for Polycystic Ovary Syndrome
Recruiting
Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS
PCOS (Polycystic Ovary Syndrome)
RecruitingPhase 1
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome
Anovulatory Infertility
RecruitingObservational study
The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world Study
Polycystic Ovary Syndrome (PCOS)
Recruiting
The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome
PCOS (Polycystic Ovary Syndrome)
Recruiting
Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography
Polycystic Ovary Syndrome (PCOS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Irma Virant-Klun, PhD principal investigator
Clinical Research Centre, University Medical Centre Ljubljana
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Polycystic Ovary Syndrome, run by University Medical Centre Ljubljana at 1 site in Slovenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Levels of EDs, toxic and essential chemical elements in biological samples (blood, urine) (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06968455, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2025.